|
|
 |
 - Easy: one-step isolation of primitive tissue and cancer stem cells with excellent purities
- Proven and tested: tool of choice in more than 500 publications
- Translatable: available for research and clinical settings
|
| Overview |
The CD133 MicroBead Kit allows the single-step isolation or depletion of CD133+ cells.
- Hematopoietic stem cells can be isolated from peripheral blood, cord blood, bone marrow, or leukapheresis product.
- Neural progenitor cells can be isolated from single-cell suspensions derived from primary neural tissues or cell lines.
- ES and iPS cell–derived neural, endothelial, or hematopoietic progenitors can be isolated from differentiated ES or iPS cell cultures1.
- Cancer stem cells can be isolated from single-cell suspensions derived from primary tumor tissue or cell lines.
|
| Details |
Background information
CD133, formerly known as AC133, recognizes epitope 1 of the CD133 antigen.2,3 It is a marker that is frequently found on multipotent progenitor cells, including immature hematopoietic stem and progenitor cells. In the hematopoietic system, CD133 is expressed on a small portion of CD34– cells4 as well as on a subset of CD34bright stem and progenitor cells in human fetal liver, bone marrow, cord blood, and peripheral blood5. CD133 has also been found to be expressed on circulating endothelial progenitor cells,6,7 fetal neural stem cells,8,9 other tissue-specific stem cells, such as renal10, prostate11, and corneal12 stem cells, cancer stem cells from tumor tissues, as well as ES and iPS cell-derived cells.
There is a growing interest in CD133-expressing stem cells from normal blood or bone marrow in regenerative medicine, for example, in the field of cardiovascular13-17, liver, or peripheral artery diseases18-20.
The CD133 MicroBeads included in the kit recognize epitope CD133/1. For quality control staining of isolated CD133+ cells, the use of CD133/2 (293C3)-PE or -APC is recommended.
Downstream applications
Isolated from hematopoietic sources, CD133+ cells can become adherent and are reported to become CD133– negative during culture.21,22 These adherent cells can then in turn give rise to non-adherent CD133+ cells that are able to differentiate into both hematopoietic and nonhematopoietic cell types.23 CD133+ cells have shown a capacity for tissue differentiation, including neural lineages24. CD133+ isolated from fetal liver25, umbilical cord blood26, bone marrow27, mobilized blood28, and skin29 are capable of in vitro differentiation into neuronal cells as well as into astrocytes,25,26,28 oligodendrocytes,26,28 and glial cells.26 CD133+ cells isolated from human fetal brain8,9,30-32 were able to form self-renewing neurospheres in vitro, and to differentiate into neurons8,32 and glia19,23. When injected into mice, human CD133+ cells differentiated into fully integrated neurons and glial cells9,30 as well as astrocytes and endothelial cells29. The CD34+CD133+ cell population, which includes CD34+CD38– cells, was shown to be capable of repopulating NOD/SCID mice33. |
| Clone | Isotype |
| AC133 | mouse IgG1 |
| |
| Figure 1 |
| Isolation of CD133+ cells from human PBMCs using the CD133 MicroBead Kit, two MS Columns, and a MiniMACS™ Separator. |
| PBMCs before separation |
 |
| Isolated CD133+ cells |
 |
|
|
|
|
| Favorites / Prices |
Request prices or add products to your favorite list.
|
| Details |
|
| Products |
| CD133 MicroBead Kit, human |
- for 2×109 total cells
Download datasheet
130-050-801
|
| CD133 MicroBead Kit, human – lyophilized |
- for 2x109 total cells
Download datasheet
130-097-049
|
|
| References |
| 1. Galic et al. (2006) Proc. Natl. Acad. Sci. U.S.A. 103: 11742–11747 |
| 2. Yin, A. H. et al. (1997) Blood 90: 5002–5012 |
| 3. Piechaczek, C. (2001) J Biol Reg Hom Agents 15: 101–102. |
| 4. Gallacher, L. et al. (2000) Blood 95: 2813–2820. |
| 5. Bühring, H. J. et al. (1999) Ann NY Acad Sci 872: 25–39. |
| 6. Gehling, U. M. et al. (2000) Blood 95: 3106–3112. |
| 7. Peichev, M. et al. (2000) Blood 95: 952–958. |
| 8. Uchida et al. (2000) Proc. Natl. Acad. Sci. USA 97: 14720–14725. |
| 9. Cummings et al. (2005) Proc. Natl. Acad. Sci. USA 102: 14069–14074. |
| 10. Bussolati, B. et al. (2005) Am. J. Pathol. 166: 545–555. |
| 11. Richardson, G. et al. (2004) J. Cell Sci. 117: 3539–3545. |
| 12. Thill, M. et al. (2004) Invest. Opthalmol. Vis. Sci. 45: 3519. |
| 13. Stamm et al. (2003) Lancet 361 (9351): 45-46. |
| 14. Stamm et al. (2007) J. Thorac. Cardiovasc. Surg. 133: 717–725. |
| 15. Klein (2007) Euro. Cardiovasc. Dis. 1: 123–125. |
| 16. Klein et al. (2007) Heart Surg. Forum 10: E66–69. |
| 17. Bartunek et al. (2005) Circulation 30: 178–183. |
| 18. Schulte am Esch et al. (2005) Stem Cells 23 (4): 463–470. |
| 19. Fürst et al. (2007) Radiology 243 (1): 171–179. |
| 20. Cañizo et al. (2007) Cytotherapy 9 (1): 99–102. |
| 21. Kuçi et al. (2003) Blood 101: 869–876. |
| 22. Kuçi et al. (2008) Cell Prolif. 41: 12–27. |
| 23. Kuçi et al. (2003) MACS&more 7 (1): 6-8. |
| 24. Kuçi et al. (2004) Abstract 2nd International Meeting, Stem Cell Network, North-Rhine Westphalia. |
| 25. Hao et al. (2003) J. Hematother. Stem Cell Res. 12: 23–32. |
| 26. Jang et al. (2004) J. Neurosci. Res. 75: 573–584. |
| 27. Padovan et al. (2003) Cell Transp. 12: 839–848. |
| 28. Piechaczek et al. (2002) Stem Cell Research Customer Report 2–3. |
| 29. Belicchi et al. (2004) J. Neurosci. Res. 77: 475–486. |
| 30. Tamaki et al. (2002) J. Neuro. Res. 69: 976–986. |
| 31. Kelly et al. (2004) Proc. Natl. Acad. Sci. USA 101: 11839–11844. |
| 32. Yu et al. (2004) Biotech. Let. 26: 1131–1136. |
| 33. de Wynter, E. A. et al. (1998) Stem Cells 16: 387–396. |
|
| MACS Stem Cell newsletter |
|
Stay current with important developments in stem cell research by subscribing to
Stem Cell Updates.
|
|
